Cite
HARVARD Citation
Schaer, D. et al. (2015). Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online].